Management

The senior management provides experience from industrial development, as well as scientific and innovation start-up companies.

Jonas Jarvius
Jonas Jarvius
CEO

Born: 1971
Chief Executive Officer since 2008

Jonas Jarvius has extensive R&D experience in the field of molecular medicine and molecular biological detection. He has co-founded several companies and is one of the founders of Q-linea. For many years, he has also held senior positions in various biotech companies and in these roles, has successfully managed projects related to molecular detection for safety applications and the manufacture and development of medical devices. He also has experience in ISO 13485 certification, a quality management standard for medical devices. In addition, he has been involved in several biotech start-ups that have evolved into large organisations.

Education: PhD in molecular medicine, Uppsala University (2006); MSc in medical science, Uppsala University (1999).
Other ongoing assignments: Jonas Jarvius is chairman of of the board of Umbrella Science AB and a member of the board of directors of QuiaPEG Pharmaceuticals Holding AB (publ).

Holdings in the Company: Jonas Jarvius owns 362,152 shares in the Company.

Mats Gullberg
Mats Gullberg
Vice President, Research Director

Born: 1971
Employed by the Company since 2013, vice president since 2016 and research director since 2017

Mats Gullberg has extensive experience in product development and commercialisation and works with intellectual property issues in biotech companies. He has previously worked with methods of microbiology and molecular biology at Uppsala University. He has vast experience in R&D projects and in running projects to identify potential future products. Over the past ten years, he has been responsible for patent and intellectual property issues, previously at the Olink AB biotech company and since 2013 at Q-linea. Since 2017, he is also responsible for the Company’s research department.

Education: PhD in medical sciences, Uppsala University (2003); MSc in pharmaceutical bioscience (microbiology), Uppsala University (1995).
Other ongoing assignments: Mats Gullberg is a director at EMPE Diagnostics AB.

Holdings in the Company: Mats Gullberg holds 350 employee share options in the Company. These options carry entitlement to acquire 7,000 shares in the Company.

Anders Lundin
Anders Lundin
CFO

Born: 1964
Chief Financial Officer and Investor Relations since 2018

Anders Lundin has more than 20 years’ experience in financial work and leadership in international organisations operating in the medical technology and pharmaceutical industries. He has previously served as the CFO of a company listed on Nasdaq Stockholm and was also responsible for a listing on the Nasdaq Stock Market in the US and the associated raising of new equity capital.

Education: MSc in economics, Uppsala University (1992).
Other ongoing assignments: Anders Lundin is a founder and member of the board of directors of CFO Akuten AB.

Holdings in the Company: Anders Lundin does not own any shares in the Company.

Nils Kristensen
Nils Kristensen
Chief Operating Officer

Born: 1963
Chief Operating Officer since 2017

Nils Kristensen has extensive experience in R&D and the commercialisation of products in the life sciences and telecom industries. He has vast experience in project management and has been running R&D projects for over 20 years. His main focus area has been manufacturing projects, in which he has worked with optimisation, lean management and quality management systems.

Education: MSc in engineering physics, Uppsala University (1998); licentiate of engineering in materials science, Uppsala University (1991).
Other ongoing assignments: Nils Kristensen is a member of the board of directors and the CEO of Kristensen Consulting AB.

Holdings in the Company: Nils Kristensen holds 505 options in the Company. These options carry entitlement to acquire 10,100 shares in the Company.

Charlotta Göransson
Charlotta Göransson
Marketing Director

Born: 1972
Employed by the Company since 2016, Marketing Director since 2017

Charlotta Göransson is a former researcher and has worked in sales and marketing in the biotech industry since 2003. She has experience in international sales as well as project management.

Education: PhD in molecular medicine, Uppsala University (2001); MSc in molecular biology, Uppsala University (1995).
Other ongoing assignments: Charlotta Göransson has no other current assignments.

Holdings in the Company: Charlotta Göransson holds 350 options in the Company. These options carry entitlement to acquire 7,000 shares in the Company

Jonas Melin
Jonas Melin
Director Product Development

Born: 1976
Director Product Development since 2017

Jonas Melin has extensive R&D experience and a deep understanding of technical and regulatory issues. He has experience in project management and has successfully led projects from development to regulatory approval. His previous positions include project manager for Meritas D-Dimer test, Troponin test and BNP test and head of technical development of Meritas troponin I.

Education: PhD in engineering science, Uppsala University (2006); MSc in technical biology, Linköping University (2002).
Other ongoing assignments: Jonas Melin is a member of the board of directors of Melin Science AB.

Holdings in the Company: Jonas Melin holds 350 options in the Company. These options carry entitlement to acquire 7,000 shares in the Company.

Karl Sköld
Karl Sköld
Director Contract Development

Born: 1974
Director Contract Development since 2018

Karl Sköld has a background as a researcher in molecular biology and pharmaceutical life sciences at Uppsala University. In the years 2007 to 2016 he was active as founder, board member and research director of Denator AB, a company that has developed and sells systems for heat stabilisation of clinical samples. Furthermore, he is co-founder of Maurten AB, which develops energy and nutritional products to athletes and the healthcare industry. In 2017, he became CEO of Umbrella Science AB whose operations were acquired by Q-linea in the summer of 2018.

Education: PhD in pharmaceutical bioscience, Uppsala University, 2006.
Other ongoing assignments: Karl Sköld is a mber of the board of directors of Hardcover AB and a deputy boardmember of Laminaria Group AB and Maurten AB.

Holdings in the Company: Karl Sköld does not own any shares in the Company.